시장보고서

상품코드

1549980

세계의 정형외과 임플란트용 황색포도상구균 감염증 진단 및 치료 시장 : 진단 및 치료, 최종사용자, 지역별 예측(-2032년)

Global Staphylococcus Aureus Infection Diagnosis and Treatment for Orthopedic Implant Market Research Report Information by Diagnosis & Treatment, by End User, by Region Forecast till 2032

발행일: 2024년 08월 | 리서치사:

Market Research Future | 페이지 정보: 영문 150 Pages | 배송안내 : 즉시배송

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

정형외과 임플란트용 황색포도상구균 감염 진단·치료 시장 규모는 2022년 23억 1,000만 달러, 2023년 24억 달러에서 예측 기간 중 4.89%의 CAGR로 추이하며, 2032년에는 38억 7,000만 달러 규모로 성장할 것으로 예측됩니다. (이)가 된다고 예측됩니다.

임플란트를 사용하는 정형외과수술 증가와 골절 발생률 증가가 시장 확대의 원동력이 되고 있습니다.

정형외과수술이 증가함에 따라 정형외과용 임플란트에 대한 황색포도상구균 감염 진단 및 치료에 대한 수요가 증가하고 있습니다. 예를 들어 2023년 7월 미국 클리블랜드 클리닉(Cleveland Clinic)은 미국에서 연간 약 80만 건의 무릎 인공관절 치환술이 시행되고 있다고 발표했습니다. 또한 미국 고관절 및 무릎 외과 의사 협회(American Association of Hip and Knee Surgeons)는 고관절 전치환술(THA) 후 심각한 우려 사항으로 인공관절 감염(PJI)을 꼽았으며, 특히 다른 건강 문제가 있는 경우 그 위험이 높아진다고 밝혔습니다. 황색포도상구균에 의한 감염 비율은 2008-2009년 26.3%에서 2020-2021년 40%로 증가할 것으로 예상됩니다.

지역별 인사이트

2022년 북미 시장이 가장 큰 시장 점유율을 차지했습니다. 이는 정형외과 임플란트에서 황색포도상구균 감염의 유병률 증가, 우수한 의료 인프라, 북미의 정형외과수술 건수 증가와 관련이 있습니다.

세계의 정형외과 임플란트용 황색포도상구균 감염증 진단·치료 시장을 조사했으며, 시장의 정의와 개요, 시장 성장에 대한 각종 영향요인 분석, 시장 규모 추이·예측, 각종 구분·지역별 내역, 경쟁 환경, 주요 기업의 개요 등을 정리하여 전해드립니다.

촉진요인
- 임플란트를 따르는 정형외과수술의 증가
- 골절의 발생률 증가
억제요인
- 엄격한 규제 요건과 긴 승인 프로세스
기회
- 정형외과 관련 황색포도상구균 감염증의 기술적 치료
- 조기진단에 대한 의식의 향상과 조기진단 제품의 개발

제5장 시장 요인 분석

Porter's Five Forces 분석
시장에 대한 COVID-19의 영향

제6장 세계의 정형외과 임플란트용 황색포도상구균 감염증 진단·치료 시장 : 진단·치료별

개요
진단
- 미생물 배양 검사
- 중합효소 연쇄 반응
- 영상 연구
치료
- 항생제
- 항균 요법
- 수술

제7장 세계의 정형외과 임플란트용 황색포도상구균 감염증 진단·치료 시장 : 최종사용자별

개요
병원
외래 수술 센터
기타

제8장 세계의 정형외과 임플란트용 황색포도상구균 감염증 진단·치료 시장 : 지역별

개요
북미
유럽
아시아태평양
기타 지역

제9장 경쟁 구도

시장 점유율 분석
경쟁 대시보드
공개 기업의 주식 개요
비교 분석 : 주요 기업의 재무 동향
주요 개발·성장 전략

제10장 기업 개요

XELLIA PHARMACEUTICALS
WELLONA PHARMA
SCHWITZ BIOTECH
MERCK KGAA
THERMO FISHER SCIENTIFIC INC
BIOMERIEUX SA
SIEMENS HEALTHINEERS AG
BECKMAN COULTER INC
F. HOFFMANN-LA ROCHE LTD
PFIZER INC

제11장 데이터 인용

KSA 24.09.20

Global Staphylococcus Aureus Infection Diagnosis and Treatment for Orthopedic Implant Market Research Report Information by Diagnosis & Treatment {(Diagnosis [Microbiological Culture Test, Polymerase Chain Reaction, and Imaging Studies {Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and Ultrasonography}], Treatment(Antibiotics, Antimicrobial Therapy, and Surgery)}, by End User (Hospitals, Ambulatory Surgery Centers, and Others), by Region (North America, Europe, Asia-Pacific, and Rest of the World) Forecast till 2032

Market Overview

Staphylococcus aureus Infection Diagnosis and Treatment for Orthopedic Implants The market was valued at USD 2.31 billion in 2022. The staphylococcus aureus infection diagnostics and treatment for orthopedic implants market is expected to increase from USD 2.40 billion in 2023 to USD 3.87 billion by 2032, with a compound yearly growth rate (CAGR) of 4.89% over the forecast period. The increasing number of orthopedic procedures involving implants, as well as the increased incidence of fractures, are driving market expansion.

The growing number of orthopedic procedures is driving up the demand for staphylococcus aureus infection diagnosis and treatment for orthopedic implants. For example, in July 2023, Cleveland Clinic (US) announced that approximately 800,000 knee replacements are performed annually in the United States. Furthermore, the American Association of Hip and Knee Surgeons identifies prosthetic joint infection (PJI) as a serious concern following total hip arthroplasty (THA), particularly when other health issues are present, which increases the risk. The rate of infections caused by staphylococcus aureus increased from 26.3% in 2008-2009 to 40% between 2020 and 2021.

Market Segment insights

The Staphylococcus Aureus Infection Diagnosis and Treatment for Orthopedic Implant Market is classified by diagnosis and treatment, with diagnosis further subdivided into microbiological culture test, polymerase chain reaction, and imaging studies.

The Staphylococcus aureus Infection Diagnosis and Treatment for Orthopedic Implant Market is segmented by end user, which includes hospitals, ambulatory surgical centers, and others.

Regional insights

The report divides the market into five regions: the United States, Europe, China, the Middle East and North Africa, and the rest of the world. In 2022, the North American staphylococcus aureus infection diagnostic and treatment for orthopedic implants market held the greatest market share. This is related to the increased prevalence of staphylococcus aureus infection in orthopedic implants, excellent healthcare infrastructure, and an increase in the number of orthopedic procedures in North America.

The Europe staphylococcus aureus infection detection and treatment for orthopedic implants market has the second-largest market share due to an increasing elderly population and favorable reimbursement policies across the country. Furthermore, Germany has the largest market share for staphylococcus aureus infection diagnosis and treatment for orthopedic implants, while the UK is expected to be the fastest-growing market in the European region.

The Asia-Pacific staphylococcus aureus infection diagnostic and treatment market for orthopedic implants is predicted to develop significantly between 2023 and 2032. This is attributable to strong population increase, government initiatives and investments, and coordination among regional healthcare partners.

The rest of the world is divided into three regions: the Middle East, Africa, and Latin America. The staphylococcus aureus infection diagnosis and treatment for orthopedic implants market in the regions is expected to increase as a result of continuing research & development activities to create novel diagnostic technologies, medicines, and preventive methods.

Major Players

Xellia Pharmaceuticals (Germany), Wellona Pharma (India), Schwitz Biotech (India), Merck KGaA (Germany), Thermo Fisher Scientific Inc (US), BioMerieux SA (France), Siemens Healthineers AG (Germany), Beckman Coulter Inc (US), Hoffmann-La Roche Ltd (Switzerland), and Pfizer Inc (US) are among the key companies in the Staphylococcus Aureus Infection Diagnosis and Treatment for Orthopedic Implant Market.

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 Data Mining Process
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 Secondary Research data flow:
3.5 PRIMARY RESEARCH:
- 3.5.1 Primary Research DATA FLOW:
- 3.5.2 Primary Research: Number of Interviews conducted
- 3.5.3 Primary Research: Regional Coverage
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 Revenue Analysis Approach
3.7 DATA FORECASTING
- 3.7.1 Data forecasting Technique
3.8 DATA MODELING
- 3.8.1 microeconomic factor analysis:
- 3.8.2 Data modeling:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 Growing number of Orthopedic surgeries associated with implants
- 4.2.2 Increasing incidence of fractures
4.3 RESTRAINTS
- 4.3.1 Stringent regulatory requirements and lengthy approval processes
4.4 OPPORTUNITY
- 4.4.1 Technological treatment for orthopedic associated staphylococcus aureus infection
- 4.4.2 Growing awareness of early diagnosis and the development of early diagnosis products

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 Threat of New Entrants
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 Threat of Substitutes
- 5.1.4 Bargaining Power of Buyers
- 5.1.5 Intensity of Rivalry
5.2 IMPACT OF COVID-19 ON THE GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET
5.3 QUALITATIVE OVERVIEW ON TREATMENT MANAGEMENT FOR STAPHYLOCOCCUS AUREUS BEFORE CULTURE AND ITS IMPACT ON HEALTHCARE COST
5.4 INDICATIVE SHARE (%) FOR IMPLANTS AFFECTED BY STAPHYLOCOCCUS AUREUS BY REGION, (2022)
5.5 TOTAL NUMBER OF JOINT REPLACEMENTS AND COMPLICATED FRACTURES REPAIRED WITH PLATES AND SCREWS
5.6 TOTAL NUMBER OF COMPLICATED FRACTURES AND JOINT REPLACEMENTS INFECTED.
5.7 TOTAL NUMBER OF COMPLICATED FRACTURES AND JOINT REPLACEMENTS INFECTED WITH STAPHYLOCOCCUS AUREUS (SA) INFECTION
5.8 TOTAL NUMBER OF COMPLICATED FRACTURES AND JOINT REPLACEMENTS REVISED SURGERIES ARE DONE BASED ON AN SA INFECTION
5.9 TOTAL NUMBER OF SYNOVIAL FLUID PUNCTURES AND TOTAL NUMBER OF SYNOVIAL FLUID PUNCTURES INFECTED WITH SA

6 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY DIAGNOSIS & TREATMENT

6.1 OVERVIEW
6.2 DIAGNOSIS
- 6.2.1 Microbiological Culture Test
- 6.2.2 Polymerase Chain Reaction
- 6.2.3 Imaging Studies
  - 6.2.3.1 Computed Tomography (CT)
  - 6.2.3.2 Magnetic Resonance Imaging (MRI)
  - 6.2.3.3 Ultrasonography
6.3 TREATMENT
- 6.3.1 Antibiotics
- 6.3.2 Antimicrobial Therapy
- 6.3.3 Surgery

7 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY END USER

7.1 OVERVIEW
7.2 HOSPITALS
7.3 AMBULATORY SURGERY CENTERS
7.4 OTHERS

8 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY REGION

8.1 OVERVIEW
8.2 NORTH AMERICA
- 8.2.1 us
- 8.2.2 canada
8.3 EUROPE
- 8.3.1 germany
- 8.3.2 France
- 8.3.3 UK
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Rest of Europe
8.4 ASIA-PACIFIC
- 8.4.1 China
- 8.4.2 India
- 8.4.3 Japan
- 8.4.4 South Korea
- 8.4.5 australia
- 8.4.6 Rest of Asia-Pacific
8.5 REST OF THE WORLD
- 8.5.1 Middle East & Africa
- 8.5.2 Latin America

9 COMPETITIVE LANDSCAPE

9.1 INTRODUCTION
9.2 MARKET SHARE ANALYSIS,
9.3 COMPETITOR DASHBOARD
9.4 PUBLIC PLAYERS STOCK SUMMARY
9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 9.6.1 Product approval

10 COMPANY PROFILES

10.1 XELLIA PHARMACEUTICALS
- 10.1.1 COMPANY OVERVIEW
- 10.1.2 FINANCIAL OVERVIEW
- 10.1.3 PRODUCTS OFFERED
- 10.1.4 KEY DEVELOPMENTS
- 10.1.5 KEY STRATEGIES
10.2 WELLONA PHARMA
- 10.2.1 COMPANY OVERVIEW
- 10.2.2 FINANCIAL OVERVIEW
- 10.2.3 PRODUCTS OFFERED
- 10.2.4 KEY DEVELOPMENTS
- 10.2.5 KEY STRATEGIES
10.3 SCHWITZ BIOTECH
- 10.3.1 COMPANY OVERVIEW
- 10.3.2 FINANCIAL OVERVIEW
- 10.3.3 PRODUCTS OFFERED
- 10.3.4 KEY DEVELOPMENTS
- 10.3.5 KEY STRATEGIES
10.4 MERCK KGAA
- 10.4.1 COMPANY OVERVIEW
- 10.4.2 FINANCIAL OVERVIEW
- 10.4.3 Products OFFERed
- 10.4.4 KEY DEVELOPMENTS
- 10.4.5 SWOT ANALYSIS
- 10.4.6 KEY STRATEGIES
10.5 THERMO FISHER SCIENTIFIC INC
- 10.5.1 COMPANY OVERVIEW
- 10.5.2 FINANCIAL OVERVIEW
- 10.5.3 products OFFERed
- 10.5.4 KEY DEVELOPMENTS
- 10.5.5 SWOT ANALYSIS
- 10.5.6 Key Strategy
10.6 BIOMERIEUX SA
- 10.6.1 COMPANY OVERVIEW
- 10.6.2 FINANCIAL OVERVIEW
- 10.6.3 products OFFERed
- 10.6.4 KEY DEVELOPMENTS
- 10.6.5 SWOT ANALYSIS
- 10.6.6 Key Strategy
10.7 SIEMENS HEALTHINEERS AG
- 10.7.1 COMPANY OVERVIEW
- 10.7.2 FINANCIAL OVERVIEW
- 10.7.3 products OFFERed
- 10.7.4 KEY DEVELOPMENTS
- 10.7.5 SWOT ANALYSIS
- 10.7.6 Key Strategy
10.8 BECKMAN COULTER INC
- 10.8.1 COMPANY OVERVIEW
- 10.8.2 FINANCIAL OVERVIEW
- 10.8.3 PRODUCTS OFFERED
- 10.8.4 KEY DEVELOPMENTS
- 10.8.5 KEY STRATEGIES
10.9 F. HOFFMANN-LA ROCHE LTD
- 10.9.1 COMPANY OVERVIEW
- 10.9.2 FINANCIAL OVERVIEW
- 10.9.3 PRODUCTS OFFERED
- 10.9.4 KEY DEVELOPMENTS
- 10.9.5 SWOT ANALYSIS
- 10.9.6 KEY STRATEGIES
10.10 PFIZER INC
- 10.10.1 COMPANY OVERVIEW
- 10.10.2 FINANCIAL OVERVIEW
- 10.10.3 productS OFFERED
- 10.10.4 KEY DEVELOPMENTS
- 10.10.5 SWOT ANALYSIS
- 10.10.6 KEY STRATEGIES